CoChat

Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles

Open access
Grandi, Alberto, Tomasi, Michele, Zanella, Ilaria, Ganfini, Luisa, Caproni, Elena, Fantappiè, Laura, Irene, Carmela, Frattini, Luca, Isaac, Samine J., König, Enrico, Zerbini, Francesca, Tavarini, Simona, Sammicheli, Chiara, Giusti, Fabiola, Ferlenghi, Ilaria, Parri, Matteo, Grandi, Guido · 2017 · Frontiers in Oncology
Cited by 77

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Bacterial outer membrane vesicles (OMVs) are naturally produced by all Gram-negative bacteria and, thanks to their plasticity and unique adjuvanticity, are emerging as an attractive vaccine platform. To test the applicability of OMVs in cancer immunotherapy, we decorated them with either one or two protective epitopes present in the B16F10EGFRvIII cell line and tested the protective activity of OMV immunization in C57BL/6 mice challenged with B16F10EGFRvIII. MATERIALS AND METHODS: gene (B16-M30) were used to decorate OMVs either alone or in combination. C57BL/6 were immunized with the OMVs and then challenged with B16F10EGFRvIII cells. Immunogenicity and protective activity was followed by measuring anti-EGFRvIII antibodies, M30-specific T cells, tumor-infiltrating cell population, and tumor growth. RESULTS: Immunization with engineered EGFRvIII-OMVs induced a strong inhibition of tumor growth after B16F10EGFRvIII challenge. Furthermore, mice immunized with engineered OMVs carrying both EGFRvIII and M30 epitopes were completely protected from tumor challenge. Immunization was accompanied by induction of high anti-EGFRvIII antibody titers, M30-specific T cells, and infiltration of CD4+ and CD8+ T cells at the tumor site. CONCLUSION: OMVs can be decorated with tumor antigens and can elicit antigen-specific, protective antitumor responses in immunocompetent mice. The synergistic protective activity of multiple epitopes simultaneously administered with OMVs makes the OMV platform particularly attractive for cancer immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2017.00253

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 77

Metadata

Authors
Grandi, A., Tomasi, M., Zanella, I., Ganfini, L., Caproni, E., Fantappiè, L., Irene, C., Frattini, L., Isaac, S. J., König, E., Zerbini, F., Tavarini, S., Sammicheli, C., Giusti, F., Ferlenghi, I., Parri, M., & Grandi, G.
Venue
Frontiers in Oncology
Published
2017-11-07
Volume
7
Pages
253-253
ISSN
2234-943X (ISSN-L)
OpenAlex
W2767964184
Cited by
77
References
4
FWCI
1.57
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles. https://app.cochat.ai/papers/10.3389/fonc.2017.00253
The paper
Grandi, A., Tomasi, M., Zanella, I., Ganfini, L., Caproni, E., Fantappiè, L., Irene, C., Frattini, L., Isaac, S. J., König, E., Zerbini, F., Tavarini, S., Sammicheli, C., Giusti, F., Ferlenghi, I., Parri, M., & Grandi, G. (2017). Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles. Frontiers in Oncology. https://doi.org/10.3389/fonc.2017.00253

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.